GlassScriptPhysician profile
Joseph A Rosa
NPI 1568421469
$8,006.04
in general payments reported to CMS, 2019-2025
10 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,684 · 2020: $50.94 · 2021: $33.86 · 2022: $102 · 2023: $251 · 2024: $366 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,803.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $2,434.26 | 2019 | |
| Abbott Laboratories | $697.64 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.58 | 2019-2025 | Jardiance |
| Insulet Corporation | $222.11 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $149.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $120.26 | 2024 | Farxiga |
| Lilly USA, LLC | $115.49 | 2019 | |
| Amgen INC. | $55.56 | 2021-2022 | |
| Novo Nordisk INC | $16.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.